Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market

Novo Nordisk’s so-called triple-G agonist allowed obesity patients in a midstage trial to lose nearly 20% of their weight after around six months’ treatment, the Danish drugmaker said Tuesday. The data look slightly better than ...